Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Synthekine

1505 O'Brien Drive
Menlo Park, CA 94025
USA
Website Company Summary Management Team
Management

CEO: Debanjan Ray (5/31/2019)
General Management: Gregory S Yedinak (3/31/2020) ; Naiyer Rizvi (5/31/2021) ; Rob Kastelein (3/31/2019)
Finance: Robin Knifsend (5/31/2021)
Technology: Martin Oft (2/28/2019)
General Counsel/Legal: Richard Murphy
Board

Outside board: (May no longer be on the board) Tim Kutzkey (The Column Group Managing Partner) Julie Grant (Canaan Partners General Partner) Nils Lonberg (Canaan Partners Executive In Residence);  Srinivas Akkaraju (Samsara BioCapital Managing Member)
Company

Business description: Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific, selective and potent cytokine therapies. Our targeted protein engineering guided by our deep experience in immunology provides transformative immunotherapies for the treatment of cancer and autoimmune disorders. Naturally occurring cytokines play a central role in many key biological processes involved in the mechanism of human diseases, but their pleiotropic activities have complicated their development as pharmaceutical agents. At Synthekine, we leverage our scientific expertise to selectively modulate cytokine agonism and generate new immunotherapies. Synthekine designs differentiated cytokine therapeutics to be both safe and efficacious, and our platform offers a chance to revolutionize how cytokine therapeutics are discovered.
Capital

Rounds: 2
Recent Fundings: Jun 2021   Sep 2020
Capital raised: 189.5M
Last Round: 107.5M
Ownership: Private  
VCs include: Canaan Partners The Column Group ;  Deerfield Management ;  RA Capital Management ;  Rock Springs Capital Emerson Collective Omega Funds Samsara BioCapital ;  Janus Henderson Investors ;  Asia Ventures
Corporate investors: Lilly

Last Tweets


 

Last Mentions


Overview
Record updated: Jul 2022
Sector: Biotech
Year Founded: 2018
Headcount: 76-100 as of Jul 2022
Rounds: 2
Recent Fundings: Jun 2021   Sep 2020
Capital Raised: 189.5M
Last Round: 107.5M
Ownership: Private